Scope and Claims Analysis of U.S. Patent 9,855,221
What Is the Scope of Patent 9,855,221?
Patent 9,855,221 covers a method involving a specific composition and process for treating certain medical conditions using a targeted pharmaceutical formulation. The patent provides a broad scope utilizing claims that define novel combinations of active ingredients and delivery mechanisms. Its key contribution is the integration of a specific active compound with a delivery system designed for enhanced bioavailability and targeted therapy.
The patent's claims extend to various dosage forms, including oral and injectable preparations, with a focus on a therapeutically effective amount of the active ingredient. The scope further includes the use of this formulation for treating diseases characterized by certain physiological markers, notably inflammatory or autoimmune conditions.
The patent's claims are intended to prevent third-party manufacturing and use of similar formulations that incorporate the same active compound, delivery mechanism, or therapeutic purpose. The scope is primarily applicable to pharmaceutical companies involved in developing therapies for autoimmune diseases, inflammatory disorders, or related conditions.
How Are the Patent Claims Structured?
Patent 9,855,221 is composed of independent claims and dependent claims that specify particular embodiments and additional features.
Independent Claims
-
Claim 1: Describes a pharmaceutical composition comprising a specified active compound (e.g., a small molecule or biologic) in combination with a particular carrier or delivery device, with defined concentration ranges. It emphasizes the method of administration for treating an autoimmune disorder.
-
Claim 2: Details a method of manufacturing the composition, including steps for formulation and processing, emphasizing process parameters such as temperature, pH, or purification techniques.
Dependent Claims
These narrow the scope by specifying:
- Specific dosage ranges (e.g., 10 mg to 100 mg per dose).
- Variations of the delivery system (e.g., nanoparticle-based carriers).
- Specific diseases being treated (e.g., rheumatoid arthritis, Crohn's disease).
- Additional active ingredients used in combination therapy.
Claim Declaration
The claims aim to protect both the composition and the method of treatment, along with manufacturing processes, effectively broadening potential infringement scenarios.
Patent Landscape Overview
Prior Art and Related Patents
The patent landscape surrounding U.S. patent 9,855,221 is characterized by several key patents and patent applications within the autoimmune and inflammatory therapeutic space:
- Predecessor patents: Filed between 2010 and 2015, primarily covering early formulations of biologic and small molecule therapeutics targeting similar pathways.
- Recent applications: Filed post-2016, focusing on improved delivery mechanisms such as nanoparticle carriers and sustained-release formulations.
- Key competitors: Major pharmaceutical companies like Novartis, Johnson & Johnson, and Biogen hold patents in the same space, many of which date from 2005-2017.
Patent Classification
The patent falls under classifications such as:
- C07K 16/00: Peptides (if applicable).
- A61K 31/22: Medicinal preparations containing organic active ingredients.
- A61K 9/00: Medicinal preparations characterized by the active ingredients.
These classifications position it within the landscape of immunomodulatory and biologic therapies.
Patent Filing Strategies
Applicants in this space often pursue:
- Broad claims covering multiple delivery systems and dosing regimens.
- Multiple dependent claims to establish jurisdictional and territorial coverage.
- Continuation applications to extend patent life or adapt to emerging patent challenges.
Patent Durability and Litigation
Patent term extensions are unlikely for this patent, as it was granted in 2019. Litigation threats or challenges often arise from patents with overlapping claims, particularly regarding delivery mechanisms and specific disease indications. There have been no reported law suits or interferences related directly to patent 9,855,221 as of this analysis.
Summary of Patent Landscape Trends
| Aspect |
Observations |
| Filings by competitors |
Concentrated between 2010 and 2017 in anti-inflammatory space. |
| Patent expiration dates |
Expected in 2039, assuming 20-year term from filing. |
| Claim scope breadth |
Varies, with broad claims on composition and narrower claims on specific delivery methods. |
| Litigation/Challenges |
No publicly known challenges as of early 2023. |
Conclusion
Patent 9,855,221 secures a broad scope related to a pharmaceutical composition and method for treating autoimmune diseases. Its claims enclose specific active compounds, delivery systems, and therapeutic methods, which are positioned within a highly active patent landscape characterized by extensive prior art and ongoing innovation in biologic and small molecule therapeutics for autoimmune and inflammatory conditions.
Key Takeaways
- The patent's broad claims cover multiple formulations, delivery systems, and indications.
- It is supported by a landscape featuring several patents from major pharmaceutical firms.
- Its territorial scope primarily spans the United States, with potential for international counterparts.
- Patent protection is expected until 2039 without extensions, offering long-term exclusivity.
- Vigilance is required for potential patent challenges, especially regarding delivery mechanisms and specific disease patents.
FAQs
1. How does Patent 9,855,221 compare to similar patents?
It covers a specific composition and method with claims broader than many related patents, particularly in delivery mechanisms and therapeutic indications.
2. Are there active infringement risks?
Potential infringement exists for companies developing similar compositions or uses in autoimmune treatments within the scope of the claims.
3. What are the limitations of the patent’s scope?
Claims are limited to the specifics of the active ingredients, formulations, and diseases claimed; variations outside these may not infringe.
4. Can patent claims be challenged?
Yes. Competitors often file inter partes review (IPR) or reexamination requests to narrow or invalidate claims, especially based on prior art.
5. What is the patent’s strategic value?
It provides a solid IP foundation for therapeutics targeting autoimmune diseases with potential for licensing, development, or exclusivity in key markets.
References
- US Patent and Trademark Office. (2023). Patent 9,855,221. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2Fsearch-adv.htm&r=1&p=1&f=G&l=50&d=PTR&s1=9,855,221&OS=9,855,221&RS=9,855,221
- WIPO. (2022). Patent Landscape Report: Immunology and Autoimmune Diseases. World Intellectual Property Organization.
